Invasive pneumococcal disease: From a tertiary care hospital in the post-vaccine era

Hum Vaccin Immunother. 2017 Apr 3;13(4):962-964. doi: 10.1080/21645515.2016.1256519. Epub 2016 Dec 1.

Abstract

A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received ≥ 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains.

Keywords: Streptococcus pneumoniae; antibiotic resistance; breakthrough infection; invasive pneumococcus disease; surveillance; vaccination; vaccine failure.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteremia / diagnosis
  • Bacteremia / microbiology
  • Bacteremia / prevention & control
  • Child
  • Child, Preschool
  • Drug Resistance, Bacterial
  • Humans
  • Infant
  • Male
  • Meningitis, Bacterial / diagnosis
  • Meningitis, Bacterial / microbiology
  • Meningitis, Bacterial / prevention & control
  • Pneumococcal Infections / diagnosis*
  • Pneumococcal Infections / microbiology*
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / immunology*
  • Serogroup
  • Streptococcus pneumoniae / classification
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / isolation & purification
  • Tertiary Care Centers
  • Treatment Failure
  • Turkey

Substances

  • Anti-Bacterial Agents
  • Pneumococcal Vaccines